Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 10;7(10):e008617. doi: 10.1161/JAHA.118.008617

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Kaplan–Meier analysis of fatal arrhythmic events. A, Event‐free survival by ECG types including non–type 1, drug‐induced type 1, and spontaneous type 1. Patients with spontaneous type 1 ECG had a worse prognosis than did patients without spontaneous type 1 ECG. No arrhythmic event occurred in patients without type 1 ECG. B, Event‐free survival by symptoms and ECG types in patients with spontaneous or drug‐induced type 1 ECG. Symptomatic patients more frequently experienced arrhythmic events than did asymptomatic patients. C, Event‐free survival by pilsicainide‐induced ventricular tachyarrhythmias (VTAs) in patients with spontaneous or drug‐induced type 1 ECG. Pilsicainide‐induced VTAs were associated with increased risk of fatal arrhythmic events. D, Event‐free survival by degree of ST elevation in patients with spontaneous or drug‐induced type 1 ECG. Patients with marked ST elevation (≥0.3 mV) in lead V1 after administration of pilsicainide had a significantly higher risk of fatal arrhythmic events than did patients with less ST elevation. Tables under the survival curve show the number of patients at risk. SCB indicates sodium channel blocker.